Levamisole/5-fluorouracil for colon cancer
Executive Summary
Drug combo has been shown to substantially reduce cancer recurrence rates, delay onset of tumor relapse and improve survival rates for patients following surgical treatment, according to study of 408 patients released by NCI Oct. 2. Treatment IND for combo was approved in May. 48% of patients treated with combo were alive five years after therapy compared to 37% who received no post-operative treatment. Study's principal investigator concluded that "the option of therapy with levamisole and 5-FU should be offered to almost all patients who have surgical treatment for high-risk, stage C [Duke's] colon cancer".